Adenomyosis: from scientific discoveries to the practical aspects of prescribing drug therapy

1. Ярмолинская М.И., Айламазян Э.К. Генитальный эндометриоз. Различные грани проблемы. С.-Пб.: Эко-Вектор, 2017. 615 с. [Yarmolinskaya M.I., Ajlamazyan E.K. Genital’nyj ehndometrioz. Razlichnye grani problemy. St. Petersburg: Ehko-Vektor, 2017. 615 p.(In Russian)].
2. Garcia L., Isaacson K. Adenomyosis: review of the literature. Journal of minimally invasive gynecology. 2011; 18(4): 428–37. doi:10.1016/j.jmig.2011.04.004
3. Zhang Q., Duan J., Liu X., Guo S.W. Platelets drive smooth muscle metaplasia and fibrogenesis in endometriosis through epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation. Mol Cell Endocrinol. 2016; 428: 1–16. doi:10.1016/j.mce.2016.03.015
4. Cai X., Shen M., Liu X., Nie J. The Possible Role of Eukaryotic Translation Initiation Factor 3 Subunit e (eIF3e) in the Epithelial-Mesenchymal Transition in Adenomyosis. Reprod Sci. 2019; 26(3): 377–85. doi:10.1177/1933719118773490.
5. Avtanski D., Garcia A., Caraballo B., Thangeswaran P., Marin S., Bianco J., et al. In vitro effects of resistin on epithelial to mesenchymal transition (EMT) in MCF-7 and MDA-MB-231 breast cancer cells - qRT-PCR and Westen blot analyses data. Data Brief. 2019; 25: 104118. doi: 10.1016/j.dib.2019.104118.
6. Li Y., Zhang Q., Liu F., Zhang Z., Zou Y., Yang B., et al. Inhibition of formin like 2 promotes the transition of ectopic endometrial stromal cells to epithelial cells in adenomyosis through a MET-like process. Gene. 2019; 710: 186–92. doi: 10.1016/j.gene.2019.06.003.
7. Qi S., Zhao X., Li M., Zhang X., Lu Z., Yang C., et al. Aberrant expression of Notch1/numb/snail signaling, an epithelial mesenchymal transition related pathway, in adenomyosis. Reprod Biol Endocrinol. 2015; 13: 96. doi: 10.1186/s12958-015-0084-2.
8. Luft F.C. Targeting epithelial-mesenchymal transition. J Mol Med. 2015; 93(7): 703–5. doi: 10.1007/s00109-015-1302-2.
9. Cho E.S., Kang H.E., Kim N.H., Yook J.I. Therapeutic implications of cancer epithelial-mesenchymal transition (EMT). Arch Pharm Res. 2019; 42(1): 14–24. doi: 10.1007/s12272-018-01108-7.
10. Greening D.W., Gopal S.K., Mathias R.A., Liu L., Sheng J., Zhu H.J., et al. Emerging roles of exosomes during epithelial-mesenchymal transition and cancer progression. Semin Cell Dev Biol. 2015; 40: 60–71. doi: 10.1016/j.semcdb.2015.02.008
11. Papageorgis P. TGFbeta Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis. J Oncol. 2015; 2015: 587193. doi: 10.1155/2015/587193
12. Khan K.N., Kitajima M., Hiraki K., Fujishita A., Nakashima M., Masuzaki H. Involvement of hepatocyte growth factor-induced epithelial-mesenchymal transition in human adenomyosis. Biol Reprod. 2015; 92(2): 35. doi:10.1095/biolreprod.114.124891.
13. Ding D., Liu X., Duan J., Guo S.W. Platelets are an unindicted culprit in the development of endometriosis: clinical and experi- mental evidence. Hum Reprod. 2015; 30(4): 812–32. https://doi.org/10.1093/humrep/dev025
14. Liu X., Shen M., Qi Q., Zhang H., Guo S.W. Corroborating evidence for platelet-induced epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation in the development of adenomyosis. Hum Reprod. 2016; 31(4): 734–49. doi: 10.1093/humrep/dew018.
15. Gonzalez D.M., Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 2014; 7: 8. doi: 10.1126/scisignal.2005189.
16. Parasuraman P., Mulligan P., Walker J.A., et al. Interaction of p190A RhoGAP with eIF3A and other translation preinitiation factors suggests a role in protein biosynthesis. J Biol Chem. 2017; 292(7): 2679–89.
17. Cai X., Shen M., Liu X., Guo S.W. Reduced Expression of Eukaryotic Translation Initiation Factor 3 Subunit e and Its Possible Involvement in the Epithelial-Mesenchymal Transition in Endometriosis. Reprod Sci. 2018; 25(1): 102–9. doi: 10.1177/1933719117702248.
18. Huang T.S., Chen Y.J., Chou T.Y., Chen C.Y., Li H.Y., Huang B.S., Tsai H.W., et al. Oestrogen-induced angiogenesis promotes adenomyosis by activating the Slug-VEGF axis in endometrial epithelial cells. J Cell Mol Med. 2014; 18(7): 1358–71. doi:10.1111/jcmm.12300.
19. Osada H. Uterine adenomyosis and adenomyoma: the surgical approach. Fertility and sterility. 2018; 109(3): 406–17. https://doi.org/10.1016/j.fertnstert.2018.01.032
20. Рухляда Н.Н., Крылов К.Ю., Бирюкова Е.И. Органосохраняющие операции при аденомиозе. Акушерство и гинекология. 2019; 5: 86–9. [Rukhliada N.N., Krylov K.Yu., Biryukova E.I. Organ-sparing surgery for adenomyosis. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2019; 5: 86–9. (in Russian)]. https://dx.doi.org/10.18565/aig.2019.5.86-89
21. Цхай В.Б., Микаиллы Г.Т., Костарева О.В., Каплунов В.А., Руф Р.Р. Беременность и роды после радикальной аденомиомэктомии и метропластики по методике Хисао Осада у женщин с диффузным аденомиозом, ассоциированным с бесплодием. Российский вестник акушера-гинеколога. 2019; 19(2): 63–7. [Tskhai V.B., Mikailly G.T., Kostareva O.V., Kaplunov V.A., Ruf R.R. Pregnancy and labor after radical adenomyomectomy and metroplasty using the procedure developed by Hisao Osada in women with diffuse adenomyosis associated with infertility. Rossiiskii vestnik akushera-ginekologa. 2019; 19(2): 63–7. (In Russian)] https://doi.org/10.17116/rosakush20191902163
22. Kishi Y., Yabuta M., Taniguchi F. Who will benefit from uterus-sparing surgery in adenomyosis-associated subfertility? Fertil steril. 2014; 102(3): 802–7. https://doi.org/10.1016/j.fertnstert.2014.05.028
23. Sizzi O., et al. Italian multicenter study on complications of laparoscopic myomectomy. J minimal invas gynecol. 2007; 14(4): 453–62. https://doi.org/10.1016/j.jmig.2007.01.013
24. Strowitzki T. Strowitzki, T., Marr, J., Gerlinger, C., Faustmann, T., Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Human Reproduction. 2010; 25(3): 633–41. https://doi.org/10.1093/humrep/dep469
25. Miyashita M., Koga K., Takamura M., Izumi G., Nagai M. et al. Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis. Gynecological Endocrinology. 2014; 30(9): 644–8. https://doi.org/10.3109/09513590.2014.911279
26. Yamanaka K., Xu B., Suganuma I., Kusuki I., Mita S., Shimizu Y., et al. Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic stromal cells in spheroid culture. Fertil steril. 2012; 97(2): 477–82. https://doi.org/10.1016/j.fertnstert.2011.11.005
27. Ярмолинская М.И., Флорова М.С. Возможности терапии диеногестом 2 мг у больных наружным генитальным эндометриозом. Проблемы репродукции. 2017; 23(1): 70–9. [Yarmolinskaya M.I., Florova M.S. The possibility of treatment with dienogest 2 mg in patients with genital endometriosis. Problemy reproduktsii. 2017; 23(1): 70–79. (In Russian)]. doi:10.17116/repro201723170-79.
28. McKinnon B.D., Bertschi D., Bersinger N.A., Mueller M.D. Inflammation and nerve fiber interaction in endometriotic pain. Trends Endocrinol Metab. 2015; 26(1): 1–10. https://doi.org/10.1016/j.tem.2014.10.003
29. Mita S., Shimizu Y., Sato A., Notsu T., Imada K., Kyo S. Dienogest inhibits nerve growth factor expression induced by tumor necrosis factor-α or interleukin-1β. Fertil steril. 2014; 101(2): 595–601. https://doi.org/10.1016/j.fertnstert.2013.10.038
30. Osuga Y., Watanabe M., Hagino A. Long‐term use of dienogest in the treatment of painful symptoms in adenomyosis. J Obst Gynaecol Research. 2017; 43(9): 1441–8. https://doi.org/10.1111/jog.13406
31. Fawzy M., Mesbah Y. Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial. Arch Gynecol Obstet. 2015; 292(6): 1267–71. https://doi.org/10.1007/s00404-015-3755-5
32. Neriishi K., Hirata T., Fukuda S., Izumi G., Nakazawa A., Yamamoto. Long‐term dienogest administration in patients with symptomatic adenomyosis. J Obstet Gynaecol Research. 2018; 44(8): 1439–44. https://doi.org/10.1111/jog.13674
33. Prathoomthong S., Prathoomthong S., Tingthanatikul Y., Lertvikool S., Rodratn N., Waiyaput W., et al. The effects of dienogest on macrophage and natural killer cells in adenomyosis: a randomized controlled study. Int J Fertil Steril. 2018; 11(4): 279–86. doi: 10.22074/ijfs.2018.5137.
34. Vercellini P., Vigano P., Somigliana E., Daguati R., Abbiati A., Fedele. Adenomyosis: epidemiological factors. Best Pract Res Clin Obstet Gynaecol. 2006; 20(4): 465–77. https://doi.org/10.1016/j.bpobgyn.2006.01.017
35. Bromley B., Shipp T. D., Benacerraf B. Adenomyosis: sonographic findings and diagnostic accuracy. J Ultrasound Med. 2000; 19(8): 529–34. https://doi.org/10.7863/jum.2000.19.8.529
36. Айламазян Э.К., Ярмолинская М.И., Молотков А.С., Цицкарава Д.З. Классификации эндометриоза. Журнал акушерства и женских болезней. 2017; 66(2): 77–92. [Aylamazyan E.K., Yarmolinskaya M.I., Molotkov A.S., Tsitskarava D.Z. Classifications of endometriosis. JOWD. 2017; 66(2): 77–92. (In Russian)]. doi: 10.17816/JOWD66277-92.
37. Pistofidis G., Makrakis E., Koukoura O., Bardis N., Balinakos P., Anaf V. Distinct types of uterine adenomyosis based on laparoscopic and histopathologic criteria. Clin Experiment Obstet Gynecol. 2014; 41(2): 113–8.
38. Kunz G., Beil D., Huppert P., Noe M., Kissler S., Leyendecker G. Adenomyosis in endometriosis—prevalence and impact on fertility. Evidence from magnetic resonance imaging. Human Reproduction. 2005; 20(8): 2309–16. https://doi.org/10.1093/humrep/dei021
39. Vercellini P., Consonni D., Dridi D., Bracco B., Frattaruolo M. Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis. Human Reproduction. 2014; 29(5): 964–77. https://doi.org/10.1093/humrep/deu041
40. Razavi M., Maleki-Hajiagha A., Sepidarkish M., Rouholamin S., Almasi-Hashiani A., Rezaeinejad M. Systematic review and meta-analysis of adverse pregnancy outcomes after uterine adenomyosis. Int J Gynaecol Obstet. 2019; 145(2): 149–57. doi: 10.1002/ijgo.12799

Received 06.02.2020

Accepted 07.02.2020